Healthcare Industry News: Eisai
News Release - June 22, 2012
Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.WOODCLIFF LAKE, N.J., June 22, 2012 -- (Healthcare Sales & Marketing Network) -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Shaji Procida to the position of Vice President and Chief Financial Officer. Previously, Ms. Procida held the position of Vice President of Finance. In her elevated role, she will have oversight and responsibility for all of Eisai's financial operations in the United States. In addition, she will continue to serve as a member of the company's Executive Committee.
Ms. Procida has had a long and successful career at Eisai. She joined the company in 1998 as Manager of Financial Consolidations and Reporting. Over the years, she has held positions of increasing responsibility within finance and accounting. In 2005, Ms. Procida was appointed into the key leadership role of Controller, where she led the accounting, financial reporting, budgeting and consolidation functions. In 2010, she was promoted to Vice President of Finance.
"Shaji is a consummate professional who has been a key advisor within our organization," said Lonnel Coats, President and CEO of Eisai Inc. "Her expertise and business leadership will continue to ensure our company's financial well-being as well as support our ongoing efforts to achieve our human health care mission of helping to improve the lives of patients and their families."
Ms. Procida holds a Bachelor of Business Administration in accounting from Pace University. She also is a member of the Financial Executive Institute and the Healthcare Businesswomen's Association (HBA). In 2006, Ms. Procida was recognized as a Rising Star by the HBA at its annual Woman of the Year event.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.Eisai.com/US.
Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.